Get the Stockscreener App
134.63
0.93%
1.245
After Hours:
134.63
Irhythm Technologies Inc stock is traded at $134.63, with a volume of 170.23K.
It is up +0.93% in the last 24 hours and down -10.81% over the past month.
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
See More
Previous Close:
$133.38
Open:
$134.09
24h Volume:
170.23K
Relative Volume:
0.34
Market Cap:
$4.30B
Revenue:
$560.03M
Net Income/Loss:
$-150.66M
P/E Ratio:
-27.70
EPS:
-4.86
Net Cash Flow:
$-87.43M
1W Performance:
-1.73%
1M Performance:
-10.81%
6M Performance:
+21.28%
1Y Performance:
+34.43%
1-Day Range:
$133.69
$135.20
1-Week Range:
$132.21
$138.41
52-Week Range:
$55.92
$157.13
Irhythm Technologies Inc Stock (IRTC) Company Profile
Name
Irhythm Technologies Inc
Sector
Industry
Phone
415-632-5700
Address
699 8TH STREET, San Francisco, CA
Compare IRTC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRTC
Irhythm Technologies Inc
|
134.63 | 4.26B | 560.03M | -150.66M | -87.43M | -4.86 |
|
ABT
Abbott Laboratories
|
125.83 | 218.75B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
107.76 | 152.62B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
400.93 | 151.01B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
92.01 | 117.43B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.91 | 44.76B | 5.54B | 4.18B | 623.10M | 7.00 |
Irhythm Technologies Inc Stock (IRTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-03-24 | Resumed | Wells Fargo | Equal Weight |
| Oct-04-24 | Initiated | Goldman | Neutral |
| Jun-20-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-11-23 | Upgrade | Citigroup | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Feb-07-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-22 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-09-22 | Downgrade | Citigroup | Buy → Neutral |
| Apr-06-22 | Initiated | Wolfe Research | Underperform |
| Feb-24-22 | Upgrade | Needham | Hold → Buy |
| Jan-18-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-12-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-11-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Dec-21-21 | Resumed | Canaccord Genuity | Buy |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Jun-02-21 | Downgrade | Citigroup | Buy → Neutral |
| Apr-13-21 | Downgrade | BTIG Research | Buy → Neutral |
| Apr-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Colliers Securities | Buy → Neutral |
| Jan-29-21 | Reiterated | Needham | Hold |
| Nov-17-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-11-20 | Initiated | Needham | Hold |
| Sep-02-20 | Initiated | Robert W. Baird | Neutral |
| Aug-07-20 | Upgrade | Colliers Securities | Neutral → Buy |
| Aug-05-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-06-20 | Initiated | BTIG Research | Buy |
| Jan-10-20 | Initiated | William Blair | Outperform |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Oct-22-19 | Initiated | Oppenheimer | Perform |
| Feb-20-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Sep-13-18 | Reiterated | Canaccord Genuity | Buy |
| Sep-06-18 | Initiated | Chardan Capital Markets | Buy |
| Aug-02-18 | Upgrade | Dougherty & Company | Sell → Neutral |
| Jul-16-18 | Downgrade | Dougherty & Company | Neutral → Sell |
| Dec-01-17 | Initiated | Dougherty & Company | Neutral |
View All
Irhythm Technologies Inc Stock (IRTC) Latest News
iRhythm Technologies Inc. Stock Analysis and ForecastFree Stock Market Knowledge Sharing - Autocar Professional
What analysts say about iRhythm Technologies Inc. stockSuperior returns - Autocar Professional
What drives iRhythm Technologies Inc. stock pricePhenomenal returns - Autocar Professional
Tempus AI Gains FDA Nod Amid Booming AI ECG Market Momentum - TradingView
Is iRhythm Technologies Inc. a good long term investmentOutstanding capital growth - jammulinksnews.com
Would iRhythm Technologies (NASDAQ:IRTC) Be Better Off With Less Debt? - simplywall.st
1 Russell 2000 Stock Worth Your Attention and 2 Facing Challenges - Yahoo Finance
Sanofi India Limited (SANOFI) Hits 52 Week HighOutstanding risk-reward balance - Autocar Professional
TEM Shares Surge on New AI Breakthrough: Should Investors Jump In? - MSN
iRhythm Technologies to Report Second Quarter 2025 Financial Results on July 31, 2025 - The Manila Times
ECG Sensor Patches Market worth $2.32 billion by 2032 with 12.0% CAGR | MarketsandMarkets™ - PR Newswire
Robert W. Baird Maintains Buy Rating on Irhythm Technologies with $160 Price Target - AInvest
(IRTC) Technical Data - news.stocktradersdaily.com
IRHYTHM INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of iRhythm Technologies, Inc.IRTC - Eastern Progress
Global Mobile ECG Devices Market Set for Rapid Expansion at 11.7% CAGR by 2032 | AliveCor, Beurer UK Ltd., Omron - The Globe and Mail
Researchers Find Wearables Help Detect Post-Op AFib - Diagnostic and Interventional Cardiology
1 Healthcare Stock on Our Buy List and 2 to Brush Off - Yahoo Finance
iRhythm Technologies (IRTC): Analyst Maintains Optimistic Outloo - GuruFocus
iRhythm (IRTC) Stock Trades Up, Here Is Why - Yahoo Finance
Wearable Blood Pressure Monitoring Patches Market CAGR 9.56% - openPR.com
Global Artificial Intelligence (AI) in Remote Patient - openPR.com
5 Revealing Analyst Questions From iRhythm’s Q1 Earnings Call - Yahoo Finance
Medical Device Leader with 40-Year Track Record and 6 Patents Joins Integer Board - Stock Titan
IRhythm Argues Patent Owner's Inaction Shouldn't Doom IPRs - Law360
iRhythm Technologies Announces Board Member Changes - The Globe and Mail
IRhythm IPR Denial Raises Key PTAB Discretion Questions - Law360
GameSquare (GAME) files equity & warrant offering; crypto plan flagged | IRTC SEC FilingForm 8-K - Stock Titan
iRhythm Technologies announces board changes as two directors retire - Investing.com Australia
iRhythm Urges Stewart to Reconsider and Clarify ‘Settled Expectations’ Basis for Discretionary Denial - IPWatchdog.com
iRhythm Technologies Announces Board Member Retirements and New Director Appointments | IRTC Stock News - GuruFocus
iRhythm Technologies Announces Board Member Retirements and New Director Appointments - The Manila Times
iRhythm Technologies Announces Retirement of Board Members and Appointment of New Directors - Quiver Quantitative
iRhythm Technologies Makes Crucial Board Changes: Two Veterans Exit as Digital Health Experts Step In - Stock Titan
IPR Denial In IRhythm Should Not Set A Blanket Rule - Law360
Morgan Stanley Raises iRhythm (IRTC) Price Target, Maintains Overweight Rating - MSN
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 8, 2024 in iRhythm Technologies Lawsuit – IRTC - ACCESS Newswire
Irhythm Technologies Inc Stock (IRTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):